| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 15 | 13 | +0,06 % | ||
| ALNYLAM PHARMACEUTICALS | 14 | 9 | -0,25 % | ||
| TEMPUS AI | 10 | 1 | +0,84 % | ||
| MODERNA | 9 | 16 | -0,05 % | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 7 | 3 | -1,01 % | ||
| NOVOCURE | 6 | 11 | -1,36 % | ||
| ZYMEWORKS | 6 | 5 | -2,51 % | ||
| JAZZ PHARMACEUTICALS | 6 | 1 | -0,78 % | ||
| BEAM THERAPEUTICS | 6 | - | 0,00 % | ||
| ROYALTY PHARMA | 6 | - | -0,17 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:42 | After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum | 182 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Several biotech and healthcare names posted notable gains in Monday's after-hours trading session, with moves driven by earnings updates, guidance announcements... ► Artikel lesen | |
| 04:30 | Biogen Gains EU Approval For High-Dose SPINRAZA Regimen In SMA | 186 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) which is comprised of 50 mg/5... ► Artikel lesen | |
| 01:31 | Why Tempus AI Stock Rose Today | 3 | The Motley Fool | ||
| Mo | Travere Therapeutics provides corporate update and 2026 outlook | 2 | Seeking Alpha | ||
| Mo | Travere meldet Rekordumsatz von 103 Mio. US-Dollar mit FILSPARI im 4. Quartal 2025 | 1 | Investing.com Deutsch | ||
| Mo | Travere reports record FILSPARI sales of $103 million in Q4 2025 | 1 | Investing.com | ||
| Mo | Faruqi & Faruqi LLP: INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics | 211 | Newsfile | Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf... ► Artikel lesen | |
| Mo | Disc Medicine appoints Lisa Amaya Price as chief human resources officer | 1 | Investing.com | ||
| Mo | Disc Medicine Inc: Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer | 1 | GlobeNewswire (USA) | ||
| Mo | BioMarin appoints Arpit Davé as chief digital and information officer | 1 | Investing.com | ||
| Mo | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | - | SEC Filings | ||
| Mo | Revolution Medicines: Stifel sieht starke Position bei Bauchspeicheldrüsenkrebs - Aktie legt zu | 5 | Investing.com Deutsch | ||
| Mo | Solid Biosciences Inc.: Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia | 2 | GlobeNewswire (USA) | ||
| Mo | Revolution Medicines stock gains as Stifel highlights strong PDAC position | 2 | Investing.com | ||
| Mo | Amphastar Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes | 2 | GlobeNewswire (USA) | ||
| Mo | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mo | Travere Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | Apellis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report | 1 | SEC Filings |